Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

PSMA-PET Agents Poised to Advance Imaging in Prostate Cancer

September 27th 2017

Thomas Hope, MD, discusses the novel technique PSMA-PET and how, if approved, it will significantly alter detection of biochemically recurrent prostate cancer.

Choueiri Covers CABOSUN Excitement and Beyond in RCC

September 27th 2017

Toni K. Choueiri, MD, sheds light on the excitement surrounding the CABOSUN and CheckMate-214 trials, and why the future of the renal cell carcinoma field lies in novel combination regimens.

Pal Provides Key ESMO Updates in GU Malignancies

September 26th 2017

Sumanta Kumar Pal, MD, discusses the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.

Radium-223 Plus Anti-VEGF Therapy Reduces Bone Turnover in Advanced RCC

September 26th 2017

Patients with advanced renal cell carcinoma with bone metastases had reductions in bone-turnover markers when treated with radium-223 dichloride and a VEGF inhibitor, although the incidence of symptomatic skeletal events remained high.

Longer Follow-Up Shows Survival Increase With Rocapuldencel-T in mRCC

September 26th 2017

Patients with metastatic renal cell carcinoma appeared to derive a substantial survival benefit with rocapuldencel-T, an immunotherapy made from dendritic cells.

Dr. McKay Discusses the CheckMate-214 Trial in RCC

September 26th 2017

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses the CheckMate-214 study in renal cell carcinoma.

Atezolizumab Approved in Europe for Lung, Bladder Cancer

September 25th 2017

The European Commission has granted regulatory approval to atezolizumab monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non-small cell lung cancer and previously-treated locally advanced or metastatic urothelial carcinoma.

Expert Talks Optimizing ADT in Prostate Cancer

September 22nd 2017

Rahul Aggarwal, MD, discussed the success of recent studies of androgen-deprivation therapy in prostate cancer, as well as its future utilization in various stages of disease.

Dr. Bosse on Rationale Behind Study of VEGF Plus Radium-223 in RCC

September 21st 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma.

Cabozantinib, Nivolumab Active in Metastatic Urothelial Carcinoma

September 20th 2017

Cabozantinib and nivolumab with or without ipilimumab show activity in genitourinary tumors, particularly urothelial carcinoma, and have manageable safety profiles.

FDA Panel Splits on Adjuvant Sunitinib in High-Risk RCC

September 20th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 6-6 on the potential approval of sunitinib for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are at high risk of recurrence.

Dr. Lalani on Neutrophil-Lymphocyte Ratio in RCC

September 19th 2017

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses neutrophil-lymphocyte ratio in renal cell carcinoma.

Dr. McGregor Discusses the Future of Treatment for RCC

September 19th 2017

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma.

FDA Approves Reduced Dose of Cabazitaxel for mCRPC

September 18th 2017

The FDA has approved a cabazitaxel (Jevtana) regimen of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer.

Enzalutamide Succeeds in Phase III Nonmetastatic CRPC Trial

September 14th 2017

Adding enzalutamide to androgen deprivation therapy (ADT) significantly improved metastasis-free survival versus ADT alone in patients with nonmetastatic castration-resistant prostate cancer, according to findings from the phase III PROSPER trial.

Dr. Pal Compares CheckMate-214 and CABOSUN Trials in RCC

September 13th 2017

Sumanta K. Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses both the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).

PFR Unaffected by Sequence of Cytoreductive Nephrectomy and Sunitinib in Patients With Synchronous mRCC

September 12th 2017

Treating primary tumors by administering targeted therapy with sunitinib (Sutent) prior to cytoreductive nephrectomy did not improve the progression-free rate at 28 weeks over a sequence of immediate CN followed by sunitinib in patients with synchronous metastatic renal cell carcinoma.

Nivolumab/Ipilimumab Improves Survival Versus Sunitinib in mRCC

September 11th 2017

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was superior to sunitinib (Sutent) monotherapy as first-line treatment of advanced or metastatic renal cell carcinoma.

Ramucirumab Improves PFS in Platinum-Refractory Urothelial Carcinoma

September 11th 2017

Ramucirumab (Cyramza) plus docetaxel improved progression-free survival over docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.

CABOSUN Update Affirms PFS Advantage With Cabozantinib Over Sunitinib in Advanced RCC

September 11th 2017

Patients with untreated advanced renal cell carcinoma lived significantly longer without disease progression when they received the multikinase inhibitor cabozantinib (Cabometyx) as initial therapy versus sunitinib (Sutent).